Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Return on Equity (2016 - 2025)

Historic Return on Equity for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to 0.47%.

  • Guided Therapeutics' Return on Equity rose 200.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.56% for FY2024, which is 4900.0% down from last year.
  • As of Q3 2025, Guided Therapeutics' Return on Equity stood at 0.47%, which was up 200.0% from 0.92% recorded in Q2 2025.
  • Guided Therapeutics' 5-year Return on Equity high stood at 1.73% for Q2 2023, and its period low was 0.33% during Q2 2021.
  • Moreover, its 5-year median value for Return on Equity was 0.71% (2022), whereas its average is 0.78%.
  • As far as peak fluctuations go, Guided Therapeutics' Return on Equity soared by 13900bps in 2023, and later crashed by -9600bps in 2024.
  • Quarter analysis of 5 years shows Guided Therapeutics' Return on Equity stood at 0.37% in 2021, then soared by 328bps to 1.57% in 2022, then plummeted by -40bps to 0.94% in 2023, then tumbled by -47bps to 0.49% in 2024, then fell by -5bps to 0.47% in 2025.
  • Its Return on Equity stands at 0.47% for Q3 2025, versus 0.92% for Q2 2025 and 1.0% for Q1 2025.